Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982449 · ClinicalTrials.gov registry record · NA
124I-FIAU Imaging in EBV and KSHV Associated Cancers
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00982449 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 12 participants.
The verdict
NCT00982449, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research is being done to determine whether viral thymidine kinase (TK) expression in Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) virus-associated tumors is sufficient to image.
Interventions
- OTHER FIAU-PET-CT-2
- OTHER FIAU-PET-CT-4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982449
The ClinicalTrials.gov registry entry for NCT00982449 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FIAU-PET-CT-2 is the first listed.
NCT00982449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982449 about?
NCT00982449 is a clinical study titled "124I-FIAU Imaging in EBV and KSHV Associated Cancers". This research is being done to determine whether viral thymidine kinase (TK) expression in Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) virus-associated tumors is sufficient to image.
What is the current status of trial NCT00982449?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2010-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00982449?
The interventions under investigation include: FIAU-PET-CT-2 (OTHER), FIAU-PET-CT-4 (OTHER).
Who is sponsoring clinical trial NCT00982449?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.